Skip to content
Screener

Vaxcyte, Inc. PCVX Business Segments — Acquired manufacturing rights

Similar metrics at other companies

Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Contract manufacturing
$4.9M-64.8%
Vir Biotechnology, Inc. logo
VIRReportable Segment — Contract manufacturing
$23.97M+70.4%
Cadence Design Systems logo
CDNSReportable Segment — Manufacturing costs
$104.48M+3.0%
IPG Photonics logo
IPGPReportable Segment — Other manufacturing expenses
$36.84M+19.3%
Ouster logo
OUSTReportable Segment — Product manufacturing costs
$22.5M+43.0%
SiTime Corporation logo
SITMReportable Segment — Other manufacturing overheads
$6.37M+7.1%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept pcvx:AcquiredManufacturingRightsExpense.

The source filing: Vaxcyte, Inc.’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:37 PM EST
Fiscal year
FY2025
Accession
0001649094-26-000007
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Operating expenses:
Research and development$794,306$476,644$332,341
Acquired manufacturing rights (Note 7)75,000
General and administrative129,36992,90260,700
Total operating expenses923,675569,546468,041
Loss from operations(923,675)(569,546)(468,041)
Other income, net:
Interest income119,718109,99462,907

Item 8. Consolidated Financial Statements and Supplementary Data.

FAQ

What is Vaxcyte, Inc.'s business segments — acquired manufacturing rights?
Vaxcyte, Inc. (PCVX) reported business segments — acquired manufacturing rights of $0 in Q4 2025.
What is the long-term trend for Vaxcyte, Inc.'s business segments — acquired manufacturing rights?
Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — acquired manufacturing rights has grown at a -100.0% compound annual growth rate (CAGR), from $23M to $0.
What does business segments — acquired manufacturing rights mean?
This metric tracks the costs associated with the acquisition of intellectual property or contractual rights related to the manufacturing processes of the segment's products. It reflects strategic investments made to secure supply chain capabilities or proprietary production technologies. These expenditures are essential for transitioning from clinical development to commercial-scale manufacturing.

Ask your AI about Vaxcyte, Inc.'s business segments — acquired manufacturing rights.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude